Drug Profile
Research programme: cardiovascular disease therapies - Sagene Pharmaceuticals
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Sagene Pharmaceuticals
- Class Antithrombotics; Cardiovascular therapies; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Thrombosis
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Thrombosis in USA
- 28 Feb 2018 Preclinical development is ongoing for cardiovascular disorders and thrombosis in USA (Sagene Pharmaceuticals pipeline, February 2018)